Published Date : Apr 18, 2016
ALBANY, New York, April 18, 2016 - MarketResearchReports.biz has announced the addition of the “Asthma Therapeutics In Asia-Pacific Markets To 2021 - High Prevalence And Launch Of Late-Stage Biologics Will Drive The Market In Spite Of Affordability Concerns” report to its offering. The detailed report contains data about the current state of the asthma market in the Asia Pacific region. It studies the market opportunities and the potential risks associated with asthma clinical trials. The report helps readers discover trends in licensing and co-developing deals pertaining to asthma products and identify the strategic consolidations shaping the asthma therapeutics industry.
Asthma is a chronic disease of the lungs that inflames and narrows the airways in the lungs, causing frequent breathlessness or shortness of the breath, tightness in the chest, and coughing. Asthma patients experience whistling or wheezing sounds in the chest as they breathe, and the severity of the disease differs from patient to patient. Asthma is genetic or may be caused due to external environmental factors. Cases of occupational asthma are also prevalent, where a person acquires asthma due to working around chemical fumes, dust, and other irritants in the air.
Asthma treatments are generally long-term control treatments involving quick relief medications and medications that provide relief from acute symptoms and exacerbations. The medications generally prescribed for long-term control of asthma include: immunomodulators, corticosteroids (ICS), leukotriene modifiers, nedocromil, cromolyn sodium, and methylxanthines. At present, only one biologic has been approved for the treatment of allergic asthma in Asia Pacific – Xolair. Thus, there still exist several unmet needs for the treatment of eosinophilic asthma.
According to the report, the rising prevalence of asthma in the global population and the increasing uptake of biologics will boost the market over the next few years. In Asia Pacific, the asthma therapeutics market comprises novel products such as Xolair, a recombinant humanized monoclonal anti-IgE antibody, Relvar/Breo, an ICS-LABA combination therapy, Seretide/Adoair, another ICS-LABA combination therapy, and Spiriva, a LAMA.
For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/686317
The report benefits readers by providing a comprehensive clinical overview of asthma by analyzing its symptoms, pathophysiology, etiology, epidemiology, diagnosis, and treatment options. It helps determine the therapeutic products, strategies, and companies that rule the market, and recognize the areas of treatment that are still unexplored. The report analyzes the market opportunities and takes into consideration the potential challenges or risks of the asthma clinical therapeutics market.
The comparison between the usage patterns, market growth projections, and the annual therapy costs between China, Australia, India, Japan, and South Korea has been presented in a detailed manner. The study helps and guides interested readers and organizations in discovering trends in co-development and licensing deals. Figures, statistics, graphs, and charts have been incorporated in the study wherever required to ensure better presentation of critical data.
To order report Call Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org